Quest Diagnostics Incorporated (DGX)
- Previous Close
136.70 - Open
136.00 - Bid --
- Ask 142.75 x 800
- Day's Range
134.95 - 138.32 - 52 Week Range
119.59 - 146.85 - Volume
1,531,800 - Avg. Volume
1,053,108 - Market Cap (intraday)
15.276B - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
18.51 - EPS (TTM)
7.43 - Earnings Date Jul 24, 2024 - Jul 29, 2024
- Forward Dividend & Yield 3.00 (2.18%)
- Ex-Dividend Date Apr 5, 2024
- 1y Target Est
146.57
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
www.questdiagnostics.com50,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DGX
Performance Overview: DGX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DGX
Valuation Measures
Market Cap
15.28B
Enterprise Value
20.16B
Trailing P/E
18.51
Forward P/E
15.65
PEG Ratio (5yr expected)
1.63
Price/Sales (ttm)
1.67
Price/Book (mrq)
2.38
Enterprise Value/Revenue
2.18
Enterprise Value/EBITDA
11.64
Financial Highlights
Profitability and Income Statement
Profit Margin
9.11%
Return on Assets (ttm)
6.20%
Return on Equity (ttm)
14.15%
Revenue (ttm)
9.29B
Net Income Avi to Common (ttm)
842M
Diluted EPS (ttm)
7.43
Balance Sheet and Cash Flow
Total Cash (mrq)
474M
Total Debt/Equity (mrq)
81.76%
Levered Free Cash Flow (ttm)
786.5M
Research Analysis: DGX
Company Insights: DGX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: DGX
Analyst Report: Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
RatingPrice TargetAnalyst Report: Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
RatingPrice TargetThe Argus Mid-Cap Model Portfolio
Small- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from global events. As well, the prices of SMID stocks generally are lower than the prices of large-caps. As well, there are long stretches in the record books when SMID stocks have outperformed large-caps. That said, SMID stocks can be risky. The standard deviation for monthly returns was 5.7% for SMID stocks over a 2003-2021 test period, versus 4.3% for large-caps. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record.
Analyst Report: Quest Diagnostics, Inc.
Quest Diagnostics is a provider of clinical diagnostic services that help to identify and treat disease and improve healthcare management. Quest is based in Secaucus, New Jersey; the stock is a component of the S&P 500.
RatingPrice Target